Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma

Cancer

Volumn 116, Issue 17, 2010, Pages 4147-4151

  Magnan, Heather ^a   Chou, Alexander J ^a   Chou, Joanne F ^a   Yeung, Henry W D ^b   Healey, John H ^a   Meyers, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Chemotherapy; Osteosarcoma; Outcome; Thallium 201

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; THALLIUM 201; VINCRISTINE; THALLIUM;

ADOLESCENT; ADULT; ARTICLE; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURGERY; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HAZARD RATIO; HUMAN; MALE; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR BIOPSY; BONE NEOPLASMS; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; PROGNOSIS; SCINTISCANNING;

ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DIAGNOSTIC IMAGING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PROGNOSIS; THALLIUM RADIOISOTOPES;

EID: 77956843816     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25375     Document Type: Article

References (29)

1. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997;44:973-989.
2. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-1606.
3. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21-26.
4. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:3641-3648.
5. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
6. Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98:415-420.
7. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
8. Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res. 2007;463:157-165.
9. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
10. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
11. Abdel-Dayem HM, Scott AM, Macapinlac HA. Thallium-201 chloride: a tumor imaging agent. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol 1. 3rd ed. Edinburgh: Churchill Livingstone; 2004:71-81.
12. Hisada K, Tonami N, Miyamae T, et al. Clinical evaluation of tumor imaging with 201 TI chloride. Radiology. 1978;129:497-500.
13. Schoder H, Kushner BH, Yeung H. PET imaging in pediatric oncology. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol 1. 3rd ed. Edinburgh: Churchill Livingstone; 2004:305-319.
14. Imbriaco M, Yeh SD, Yeung H, et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer. 1997;80:1507-1512.
15. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18.
16. Harrell F. Regression Modeling Strategies. New York: Springer-Verlag New York, Inc; 2001.
17. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
18. Rosen G, Loren GJ, Brien EW, et al. Serial thallium-201 scintigraphy in osteosarcoma. Correlation with tumor necrosis after preoperative chemotherapy. Clin Orthop Relat Res. 1993;(293):302-306.
19. Kunisada T, Ozaki T, Kawai A, Sugihara S, Taguchi K, Inoue H. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy: angiography compared with thallium-201 scintigraphy. Cancer. 1999;86:949-956.
20. Lin J, Leung WT, Ho SK, et al. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Eur J Nucl Med. 1995;22:553-555.
21. Ohtomo K, Terui S, Yokoyama R, et al. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med. 1996;37:1444-1448.
22. Ilhan IE, Vural G, Berberoglu S, Kapucuoglu N, Cila A, Eke S. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response. Pediatr Hematol Oncol. 2005;22:153-162.
23. Kaste SC, Billips C, Tan M, et al. Thallium bone imaging as an indicator of response and outcome in nonmetastatic primary extremity osteosarcoma. Pediatr Radiol. 2001;31:251-256.
24. Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001;91:2230-2237.
25. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003;228:271-278.
26. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643.
27. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
28. Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography. Cancer. 2002;94:3277-3284.
29. Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115:3519-3525.